In the EXHALE-4 study, dexpramipexole met the primary endpoint with statistically significant improvement in lung function compared with placebo Dexpramipexole demonstrated statistically significant reduction in blood absolute eosinophil count (AEC) compared with placebo Full results will be presented at an upcoming … Continued
Story by Sam Lawley and Jon Brady The boss of Omaze has suggested his firm could be forced to build luxury homes to give away in its famous prize draws – because the readily available supply of posh residences is drying … Continued
Expected readouts in obesity, lung cancer and atopic dermatitis headline a series of study results that could give the biotechnology sector a boost in another down year. Published Jan. 2, 2025 • Updated June 30, 2025 By BioPharma Dive staff … Continued
Initial Series A raise of $350 million funding Areteia Phase III development program of dexpramipexole in eosinophilic asthma, including three ongoing Phase III clinical trials Additional funding of $75 million will support significant expansion of the existing program, including adding … Continued
Yieldstreet is acquiring Cadre, a real estate investment platform with a mission to democratize access to investing, particularly in commercial real estate, Fortune is the first to report. Cadre’s founder and chief executive, Ryan Williams, will remain at the helm … Continued
(RTTNews) – Clinical-stage biopharmaceutical company Biohaven Ltd. (BHVN) Tuesday announced positive biomarker data from the Phase 1 electroencephalogram (EEG) biomarker study of its lead asset BHV-7000, proposed for the treatment of epilepsy. Examination of EEG in healthy subjects administered single … Continued
Through these collaborative efforts, SABIC aims to help reduce the carbon footprint in the agricultural supply chain, especially after the company obtained the world’s first independent certifications for low-carbon ammonia and blue hydrogen from TÜV Rheinland Group Riyadh: Agri-Nutrients SABIC, … Continued
In the EXHALE-1 study, dexpramipexole significantly reduced blood absolute eosinophil count (AEC) at week 12 versus placebo All three active doses achieved significance (150-mg, 75-mg, and 37.5-mg BID) Dexpramipexole displayed a favorable safety profile and was well tolerated, with 97% … Continued
Jul. 11, 2023, 07:00 AM Co-Founder Milind Mehere to transition to senior advisor and continue on Board of Directors Leadership Transition Comes as Yieldstreet Enters Next Phase of Growth NEW YORK, July 11, 2023 /PRNewswire/ — Yieldstreet (the “Company”), the … Continued
CHAPEL HILL, N.C.–(BUSINESS WIRE)–Areteia Therapeutics announced today that the first patients have been dosed in both the EXHALE-2 and EXHALE-4 trials as part of its overall Phase III clinical program investigating the efficacy and safety of oral dexpramipexole in severe … Continued
